The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...